Immunome (IMNM)
NASDAQ:IMNM
Want to see IMNM full AI Analyst Report?
IMNM Stock Chart & Stats
$23.26
-$0.28(-2.60%)
At close: 4:00 PM EST
$23.26
-$0.28(-2.60%)
Day’s Range― - ―
52-Week Range$6.97 - $27.65
Previous CloseN/A
Volume79.27K
Average Volume (3M)1.39M
Market Cap
$2.65B
Enterprise Value$1.51B
Total Cash (Recent Filing)$653.48M
Total Debt (Recent Filing)$3.85M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
May 07, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding113,133,200
10 Day Avg. Volume1,019,775
30 Day Avg. Volume1,394,561
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.96
Price to Sales (P/S)270.32
P/FCF Ratio-9.35
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue218.18
Enterprise Value/Gross Profit-34.62
Enterprise Value/Ebitda-7.26
Forecast
1Y Price Target
$35.36Price Target Upside52.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.4
Revenue Forecast (FY)$9.83M
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationPhase III results showing stronger disease control and greater tumor shrinkage versus the only approved therapy suggest varegacestat could become a preferred once‑daily oral option and improve patient quality of life.
Pipeline OptionalityA growing portfolio that includes antibody‑drug conjugates, a clinical‑ready radioligand, and early lymphoma signals provides multiple development paths and reduces reliance on a single asset.
Regulatory FilingManagement plans to submit a regulatory application for varegacestat based on strong late‑stage data, positioning the company for potential approval and a commercial launch.
Bears Say
Cash RunwayLimited cash resources combined with high cash burn create financing risk that may necessitate additional capital and could pressure program timelines.
Competitive AdoptionCompetitor efforts to identify patients with advanced tools and to maximize retention through adverse‑event management could make community adoption of varegacestat more difficult and limit market share.
Market SentimentElevated short interest signals investor skepticism that could amplify selling pressure on the stock during adverse news or funding events.
Immunome News
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $6.97 and its highest was $27.65 in the past 12 months.
What is Immunome’s market cap?
Immunome’s market cap is $2.65B.
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is May 07, 2026 which is in 19 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on Mar 03, 2026. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.59 by -$0.17.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -0.55.
How many shares outstanding does Immunome have?
Immunome has 113,133,200 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.59. Following the earnings report the stock price went up 4.55%.
Which hedge fund is a major shareholder of Immunome?
Currently, no hedge funds are holding shares in IMNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunome Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.36 (52.02% Upside)
$35.36 (52.02% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 5.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $791.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
224.40%
12-Months-Change
Fundamentals
Return on Equity
-57.61%
Trailing 12-Months
Asset Growth
184.38%
Trailing 12-Months
Company Description
Immunome
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
IMNM Stock 12 Month Forecast
Average Price Target
$35.36
▲(52.02% Upside)
Technical Analysis
Ownership Overview
4.75% Insiders
33.29% Mutual Funds
0.35% Other Institutional Investors
49.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---